Table 2.

Changes in the clinical parameters during the observation period.

	IGlar biosimilar (n = 34)			IGlar U300 (n = 102)
	Baseline	6 months	p	Baseline	6 months	p
Body mass index (kg/m2)	25.2 ± 5.3	24.9 ± 5.3	.17	25.9 ± 4.2	25.7 ± 4.3	.16
Body weight (kg)	65.9 ± 15.5	65.1 ± 15.2	.18	67.9 ± 13.7	67.6 ± 13.8	.16
Dose of basal insulin (unit/day)	11.6 ± 6.2	11.6 ± 6.9	.91	12.0 ± 6.3	12.8 ± 7.3	<.01
Dose of bolus insulin (unit/day)	8.6 ± 9.2	7.7 ± 9.1	.12	8.7 ± 10.0	8.5 ± 9.6	.50
Dose of total insulin (unit/day)	20.2 ± 12.4	19.3 ± 12.6	.30	20. ±13.4	21.3 ± 14.1	.18
HbA1c (%)	7.9 ± 1.1	7.8 ± 1.0	.48	7.9 ± 1.2	7.8 ± 1.2	.43
Hypoglycemia within the past 6 months (%)	12	12	1.00	13	2	<.01
Addition of anti-diabetic agents (%)	–	6		–	6
Decrease of anti-diabetic agents (%)	–	12		–	9

Abbreviations. IGlar, insulin glargine; U300, 300 U/mL.